AR006514A1 - Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende - Google Patents
Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprendeInfo
- Publication number
- AR006514A1 AR006514A1 ARP960103427A AR10342796A AR006514A1 AR 006514 A1 AR006514 A1 AR 006514A1 AR P960103427 A ARP960103427 A AR P960103427A AR 10342796 A AR10342796 A AR 10342796A AR 006514 A1 AR006514 A1 AR 006514A1
- Authority
- AR
- Argentina
- Prior art keywords
- macrolide
- producing
- pharmaceutical composition
- produce
- inclusive
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003120 macrolide antibiotic agent Substances 0.000 abstract 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- 229930105110 Cyclosporin A Natural products 0.000 abstract 1
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- 241000187747 Streptomyces Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229930182912 cyclosporin Natural products 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 238000006073 displacement reaction Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000003018 immunoassay Methods 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 230000001861 immunosuppressant effect Effects 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/465—Streptomyces
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se refiere a un macrólido el cual tiene: i) las posiciones 2 a 6 inclusive, del anillo macrocíclico que se proporcionan por un residuo de ácidopiperidazinilcarboxílico; y/o ii)las posiciones 7 a 9 inclusive, del anillo macrocíclicoque se proporcionan por un residuo alfa-aminoácido aromático;y/o iii) las posiciones 10 a 12 inclusive, del anillo macrocíclico que se proporcionan por un residuo alfa-aminoácido alifático, en forma libreo protegida, o una sal del mismo.Además, s e refiere al uso de dicho macrólido para la preparación de un medicamento para uso como inmunosupresor, al uso dedicho macrólido como un reactivo en un inmunoensayo de desplazamiento para una ciclosporina u otros compuestos que unenciclofilina , a un proceso paraproducir dicho macrólido, a un aislado biológicamente puro de la cepa Streptomyces sp A92-308110 (DSM 9954) o un mutante, recombinante o formamodificada del mismo, el cual es capaz de producir dichomacrólido, y a una composición farmacéutica que comprende a dicho macrólido en asociación con undiluyente o portador farmacéuticamente aceptable.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9513596.8A GB9513596D0 (en) | 1995-07-04 | 1995-07-04 | Organic compounds |
| GBGB9515495.1A GB9515495D0 (en) | 1995-07-28 | 1995-07-28 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR006514A1 true AR006514A1 (es) | 1999-09-08 |
Family
ID=26307320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960103427A AR006514A1 (es) | 1995-07-04 | 1996-07-03 | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0836616A1 (es) |
| JP (1) | JPH11509092A (es) |
| KR (1) | KR19990028724A (es) |
| CN (1) | CN1193979A (es) |
| AR (1) | AR006514A1 (es) |
| AU (1) | AU708004B2 (es) |
| BR (1) | BR9609324A (es) |
| CA (1) | CA2224715A1 (es) |
| CO (1) | CO4750713A1 (es) |
| CZ (1) | CZ424297A3 (es) |
| HU (1) | HUP9802320A3 (es) |
| IL (1) | IL122844A0 (es) |
| NO (1) | NO980016L (es) |
| PL (1) | PL324346A1 (es) |
| SK (1) | SK498A3 (es) |
| TR (1) | TR199800001T1 (es) |
| WO (1) | WO1997002285A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6124453A (en) * | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| GB9811854D0 (en) * | 1998-06-02 | 1998-07-29 | Ciba Geigy Ag | Organic compounds |
| US7368423B1 (en) * | 2001-12-05 | 2008-05-06 | The Scripps Research Institute | Composition and method for treating chronic allograft rejection |
| EP1768662A2 (en) | 2004-06-24 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
| AR054778A1 (es) | 2005-06-17 | 2007-07-18 | Novartis Ag | Uso de sangliferina en hcv |
| US8067024B2 (en) | 2006-02-10 | 2011-11-29 | Medtronic Vascular, Inc. | Medical devices to prevent or inhibit restenosis |
| CN101289440B (zh) * | 2007-06-29 | 2010-08-25 | 中国热带农业科学院热带生物技术研究所 | 一种多烯大环类化合物及其制备方法与应用 |
| WO2010034243A1 (en) * | 2008-09-24 | 2010-04-01 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Novel gene cluster |
| WO2011098808A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| WO2011098805A1 (en) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| ES2541853T3 (es) | 2010-02-09 | 2015-07-27 | Neurovive Pharmaceutical Ab | Compuestos basados en sangliferina |
| GB201008123D0 (en) | 2010-05-17 | 2010-06-30 | Biotica Tech Ltd | Novel compounds |
| UY33775A (es) | 2010-12-10 | 2012-07-31 | Gilead Sciences Inc | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos |
| CA2822347C (en) * | 2010-12-20 | 2019-11-05 | Neurovive Pharmaceutical Ab | Sanglifehrin derivatives and methods for their production |
| JO3063B1 (ar) | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
| GB201118334D0 (en) | 2011-10-24 | 2011-12-07 | Biotica Tech Ltd | Novel dosage form |
| CN104703991B (zh) | 2012-06-08 | 2018-03-23 | 吉利德科学公司 | 黄病毒科病毒的大环抑制剂 |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| PL2859009T3 (pl) | 2012-06-08 | 2018-03-30 | Gilead Sciences, Inc. | Makrocykliczne inhibitory wirusów flaviviridae |
| CN110062626A (zh) | 2016-11-18 | 2019-07-26 | 纽维制药有限公司 | sanglifehrin大环类似物作为抗癌化合物的用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9318144D0 (en) * | 1993-09-01 | 1993-10-20 | Sandoz Ltd | Organic compounds |
| WO1995015328A1 (en) * | 1993-11-30 | 1995-06-08 | Abbott Laboratories | Macrocyclic immunomodulators with novel cyclohexyl ring replacements |
-
1996
- 1996-07-03 AR ARP960103427A patent/AR006514A1/es unknown
- 1996-07-04 KR KR1019980700022A patent/KR19990028724A/ko not_active Withdrawn
- 1996-07-04 WO PCT/EP1996/002952 patent/WO1997002285A1/en not_active Ceased
- 1996-07-04 CN CN96196487A patent/CN1193979A/zh active Pending
- 1996-07-04 AU AU65193/96A patent/AU708004B2/en not_active Ceased
- 1996-07-04 PL PL96324346A patent/PL324346A1/xx unknown
- 1996-07-04 CO CO96034982A patent/CO4750713A1/es unknown
- 1996-07-04 SK SK4-98A patent/SK498A3/sk unknown
- 1996-07-04 TR TR1998/00001T patent/TR199800001T1/xx unknown
- 1996-07-04 HU HU9802320A patent/HUP9802320A3/hu unknown
- 1996-07-04 EP EP96924886A patent/EP0836616A1/en not_active Withdrawn
- 1996-07-04 CZ CZ974242A patent/CZ424297A3/cs unknown
- 1996-07-04 IL IL12284496A patent/IL122844A0/xx unknown
- 1996-07-04 CA CA002224715A patent/CA2224715A1/en not_active Abandoned
- 1996-07-04 BR BR9609324A patent/BR9609324A/pt not_active Application Discontinuation
- 1996-07-04 JP JP9504832A patent/JPH11509092A/ja active Pending
-
1998
- 1998-01-02 NO NO980016A patent/NO980016L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP9802320A2 (hu) | 1999-02-01 |
| EP0836616A1 (en) | 1998-04-22 |
| SK498A3 (en) | 1998-07-08 |
| AU6519396A (en) | 1997-02-05 |
| HUP9802320A3 (en) | 1999-03-29 |
| KR19990028724A (ko) | 1999-04-15 |
| CO4750713A1 (es) | 1999-03-31 |
| MX9800217A (es) | 1998-07-31 |
| JPH11509092A (ja) | 1999-08-17 |
| PL324346A1 (en) | 1998-05-25 |
| WO1997002285A1 (en) | 1997-01-23 |
| CZ424297A3 (cs) | 1998-04-15 |
| NO980016L (no) | 1998-03-02 |
| CN1193979A (zh) | 1998-09-23 |
| BR9609324A (pt) | 1999-05-25 |
| TR199800001T1 (xx) | 1998-04-21 |
| CA2224715A1 (en) | 1997-01-23 |
| AU708004B2 (en) | 1999-07-29 |
| NO980016D0 (no) | 1998-01-02 |
| IL122844A0 (en) | 1998-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR006514A1 (es) | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende | |
| ATE92080T1 (de) | Isolierung und strukturbestimmung des zytostatischen linearen depsipeptids dolastatin 15. | |
| DE68909139D1 (de) | Substanz FR901228 und deren Herstellung. | |
| DK0431350T3 (da) | Ny polypeptidforbindelse og fremgangsmåde til fremstilling deraf | |
| DE69003168D1 (de) | Isolierung und Strukturbestimmung des zytostatischen linearen depsipeptiden Dolastatin 13 und Dehydrodolastatin 13. | |
| KR890000518A (ko) | 시클릭 펩톨라이드 | |
| ATE311405T1 (de) | Hochreine lipopeptide, lipopeptid mizellen, deren herstellung und arzneimittel | |
| ES2149276T3 (es) | Imidazo(4,5-c)piridin-4-aminas. | |
| ES2103857T3 (es) | Peptidos ciclicos y su uso. | |
| LU90943I2 (fr) | Kineret-anakinra et ses dérivés pharmaceutiquement acceptables | |
| ATE377076T1 (de) | Humanes cytokin als ligand des zalpha rezeptors und dessen verwendungen | |
| ES2096262T3 (es) | Nuevas cyclosporins modificadas en la posicion 1. | |
| GB2380675A (en) | Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives | |
| MX9703484A (es) | Compuestos de lactona macrociclicos y su procedimiento de produccion. | |
| KR100283503B1 (ko) | 면역억제제의 제조방법 및 이에 사용되는 신규 미생물 | |
| BR9810002A (pt) | Preparação de <244>1-at nativa purificada cromatograficamente, processo para a preparação da mesma, e, utilização de um material de suporte | |
| EA200100347A1 (ru) | Метод и композиция для лечения и профилактики туберкулеза | |
| Fusetani et al. | Nazumamide A, a thrombin-inhibitory Tetrapeptide, from a marine sponge, theonella sp. | |
| DE68927759D1 (de) | Cyclische Peptide mit Substance P-und Substance K-antagonistischer Aktivität | |
| CZ303552B6 (cs) | Memnopeptid, farmaceutická kompozice tento memnopeptid obsahující, zpusob prípravy tohoto memnopeptidu a jeho použití k príprave léciva | |
| GB8802229D0 (en) | Ws-9326 & its derivatives | |
| ES2137544T3 (es) | Procedimiento para la preparacion de un preparado biologico terapeutico sin riesgo de infeccion por virus. | |
| BR9910763A (pt) | Proteìna não-estrutural 4 (nsp4) de rotavìrus composição antigênica, processos para proteger um hospedeiro mamìfero contra doença causada por rotavìrus, e para melhorar sintomas diarréicos em um hospedeiro mamìfero, sequência de ácido nucleico isolada e purificada, plasmìdeo contendo uma sequência de ácido nucleico isolada e purificada, célula hospedeira, e, processo para produzir uma forma alternativa de nsp4 de rotavìrus | |
| JPH0338280B2 (es) | ||
| GB8928811D0 (en) | An activator for damaged neurocytes for the prevention and treatment of disease |